company background image
MIPH

MINAPHARM Pharmaceuticals CASE:MIPH Stock Report

Last Price

ج.م139.71

Market Cap

ج.م1.7b

7D

-0.2%

1Y

31.9%

Updated

04 Dec, 2022

Data

Company Financials
MIPH fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance3/6
Financial Health5/6
Dividends1/6

MIPH Stock Overview

MINAPHARM Pharmaceuticals operates as a pharmaceutical company primarily in Egypt and the Middle East.

MINAPHARM Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for MINAPHARM Pharmaceuticals
Historical stock prices
Current Share Priceج.م139.71
52 Week Highج.م192.98
52 Week Lowج.م103.21
Beta0.17
1 Month Change-14.94%
3 Month Change-14.94%
1 Year Change31.89%
3 Year Change64.46%
5 Year Change99.59%
Change since IPO1,436.81%

Recent News & Updates

Recent updates

Shareholder Returns

MIPHEG PharmaceuticalsEG Market
7D-0.2%8.2%3.9%
1Y31.9%12.1%14.4%

Return vs Industry: MIPH exceeded the EG Pharmaceuticals industry which returned 12.1% over the past year.

Return vs Market: MIPH exceeded the EG Market which returned 14.4% over the past year.

Price Volatility

Is MIPH's price volatile compared to industry and market?
MIPH volatility
MIPH Average Weekly Movement4.2%
Pharmaceuticals Industry Average Movement4.7%
Market Average Movement5.5%
10% most volatile stocks in EG Market9.0%
10% least volatile stocks in EG Market3.4%

Stable Share Price: MIPH is less volatile than 75% of EG stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: MIPH's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1958n/aWafik El Bardissihttps://www.minapharm.com

MINAPHARM Pharmaceuticals operates as a pharmaceutical company primarily in Egypt and the Middle East. The company’s products include Angiofox capsules, Artelac and Berberil eye drops; Bon-one, Ciprodiazole, Dumozol, Hydroquine, and Burinex tablets; Chlorhexidine; DICYNONE; Corneregel fluid and ophthalmic gel; Betolvex and Fleboton ampoules; Deponit patches; Dexagel viscous eye drops; Doxiproct plus and Doxiproct ointment; Doxium capules; Broncho-Vaxom capsules for adults and infants; Broncho-Vaxom infant sachets; Netophtiole plus eye drops; Extrauma cream; and Ophtatrov and Optatrov plus. It also provides Ferroduonal, Lipanthyl, Parafon, Ribavirin, Uro-Vaxom, Ursofalk, Ursoplus, Ursotwin, and Ferro Sanol Gyn capsules; Gyno-Pevaryl, Pevisone, Srilane, and Pevaryl cream; Gonapure; Hair Plus Back 2% and 5%; Hair Plus Back Topical FOAM; Lucidril 500; Lucidril, Salofalk, Trimed flu, XerovirinC, Pixcolt, and Ossopan tablets; Thrombexx ampoules, cream, and gel; Vidisept N drops; and Luciforte, Oxytocin, Reiferon Retard, and Nausilex ampoules.

MINAPHARM Pharmaceuticals Fundamentals Summary

How do MINAPHARM Pharmaceuticals's earnings and revenue compare to its market cap?
MIPH fundamental statistics
Market Capج.م1.72b
Earnings (TTM)ج.م548.83m
Revenue (TTM)ج.م3.44b

3.1x

P/E Ratio

0.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MIPH income statement (TTM)
Revenueج.م3.44b
Cost of Revenueج.م2.07b
Gross Profitج.م1.37b
Other Expensesج.م824.97m
Earningsج.م548.83m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)44.64
Gross Margin39.92%
Net Profit Margin15.95%
Debt/Equity Ratio79.1%

How did MIPH perform over the long term?

See historical performance and comparison

Dividends

2.1%

Current Dividend Yield

6%

Payout Ratio